Cervical Cancer Regression Measured Using Weekly Magnetic Resonance Imaging During Fractionated Radiotherapy: Radiobiologic Modeling and Correlation With Tumor Hypoxia
- Radiation Medicine Program, Princess Margaret Hospital/Ontario Cancer Institute, University Health Network, Toronto, ON (Canada)
- Department of Medical Imaging, Princess Margaret Hospital/Ontario Cancer Institute, University Health Network, Toronto, ON (Canada)
- Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada)
Purpose: To measure regression of cancer of the uterine cervix during external beam radiotherapy using magnetic resonance imaging, derive radiobiologic parameters from a mathematical model of tumor regression, and compare these parameters with the pretreatment measurements of tumor hypoxia. Methods and Materials: A total of 27 eligible patients undergoing external beam radiotherapy for cervical cancer underwent weekly magnetic resonance imaging scans. The tumor volume was assessed on each of these scans and the rate of regression plotted. A radiobiologic model was formulated to simulate the effect on tumor regression of the surviving proportion of cells after 2 Gy (SP{sub 2}), the cell clearance constant (clearance of irreparably damaged cells from the tumor [T{sub c}]), and accelerated repopulation. Nonlinear regression analysis was used to fit the radiobiologic model to the magnetic resonance imaging-derived tumor volumes and to derive the estimates of SP{sub 2} and T{sub c} for each patient. These were compared to the pretreatment hypoxia measurements. Results: The initial tumor volume was 8-209 cm{sup 3}. The relative reduction in volume during treatment was 0.02-0.79. The simulations using representative values of the independent biologic variables derived from published data showed SP{sub 2} and T{sub c} to strongly influence the shape of the volume-response curves. Nonlinear regression analysis yielded a median SP{sub 2} of 0.71 and median T{sub c} of 10 days. Tumors with a high SP{sub 2} >0.71 were significantly more hypoxic at diagnosis (p = 0.02). Conclusion: The results of our study have shown that cervical cancer regresses during external beam radiotherapy, although marked variability is present among patients and is influenced by underlying biologic processes, including cellular sensitivity to radiotherapy and proliferation. Better understanding of the biologic mechanisms might facilitate novel adaptive treatment strategies in future studies.
- OSTI ID:
- 21039709
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 70, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2007.06.033; PII: S0360-3016(07)01150-9; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Onset Time of Tumor Repopulation for Cervical Cancer: First Evidence From Clinical Data
Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)